tiprankstipranks
Trending News
More News >

Fortrea Holdings Inc. Adopts Stockholder Rights Plan

Story Highlights
  • Fortrea adopted a stockholder rights plan on June 11, 2025, to protect stockholder interests.
  • The plan prevents hostile takeovers by allowing discounted share purchases if 10% ownership is reached.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Fortrea Holdings Inc. Adopts Stockholder Rights Plan

Confident Investing Starts Here:

Fortrea Holdings Inc. ( (FTRE) ) has provided an announcement.

On June 11, 2025, Fortrea Holdings Inc. announced the adoption of a limited-duration stockholder rights plan, effective immediately, to protect the interests of its stockholders amidst significant dislocation in its stock trading price. The plan, which expires on June 10, 2026, aims to ensure fair treatment in takeover scenarios and prevent hostile acquisitions without appropriate premiums. It allows stockholders to purchase additional shares at a discount if any entity acquires 10% or more of Fortrea’s common stock, encouraging potential acquirers to engage directly with the Board.

The most recent analyst rating on (FTRE) stock is a Hold with a $21.00 price target. To see the full list of analyst forecasts on Fortrea Holdings Inc. stock, see the FTRE Stock Forecast page.

Spark’s Take on FTRE Stock

According to Spark, TipRanks’ AI Analyst, FTRE is a Neutral.

Fortrea Holdings Inc. presents a complex investment case with significant financial and operational challenges. The most notable factors include negative profitability and high leverage, which weigh heavily on the stock’s outlook. While there are positive initiatives in pipeline management and cost reduction, these are overshadowed by the financial strain from goodwill impairment. Technical indicators and valuation further contribute to a cautious stance.

To see Spark’s full report on FTRE stock, click here.

More about Fortrea Holdings Inc.

Fortrea Holdings Inc. (Nasdaq: FTRE) is a leading global provider of clinical development solutions to the life sciences industry. The company partners with biopharmaceutical, biotechnology, medical device, and diagnostic companies to drive healthcare innovation and accelerate life-changing therapies to patients. Fortrea offers phase I-IV clinical trial management, clinical pharmacology, and consulting services, leveraging over three decades of experience across more than 20 therapeutic areas.

Average Trading Volume: 2,973,078

Technical Sentiment Signal: Sell

Current Market Cap: $489.6M

For detailed information about FTRE stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1